Breaking News
Get 45% Off 0
Is it finally time to sell Nvidia ahead of earnings?
Read More

Here's Why You Should Invest In DaVita (DVA) Stock Right Now

By Zacks Investment ResearchStock MarketsMar 27, 2020 08:46AM ET
www.investing.com/analysis/heres-why-you-should-invest-in-davita-dva-stock-right-now-200519592
Here's Why You Should Invest In DaVita (DVA) Stock Right Now
By Zacks Investment Research   |  Mar 27, 2020 08:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
-0.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DVA
-0.51%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ARAY
-1.94%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
COO
-0.73%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
WST
+0.53%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

DaVita Inc. (NYSE:DVA) continues to benefit from solid and steadily expanding international presence, DaVita Kidney Care and prudent acquisition of dialysis centers.

In a year’s time, shares of DaVita have rallied 37.9% against the industry's decline 17.6%. Meanwhile, the S&P 500 Index has fallen 12.9%.

With a market capitalization of $9.26 billion, DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure. The company’s earnings are anticipated to grow 20.4% over the next five years. It has a trailing four-quarter positive earnings surprise of 10.8%, on average.

The stock also has a VGM Score of A. Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2 (Buy), are better picks than most.

Let’s delve deeper into the factors that substantiate DaVita’s Zacks Rank #1 at present.




Factors Driving DaVita

DaVita is steadily expanding in the international markets. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances and acquisitions of dialysis centers.

These are anticipated to help DaVita deliver more efficient patient care. Currently, the company is looking to expand in major European and Asian countries via acquisitions and partnerships.

DaVita Kidney Care, the major revenue-generating segment of DaVita, specializes in a broad array of dialysis services, thereby significantly contributing to the top line. Notably, fourth-quarter U.S. dialysis and related lab services revenues amounted to $2.77 billion, up 1.8% on a year-over-year basis.

Acquiring dialysis centers and businesses that own and operate dialysis centers and other ancillary services is DaVita’s preferred business strategy. These initiatives have contributed significantly to the company’s top line.

During fourth-quarter 2019, DaVita opened a total of 31 new dialysis centers in the country. Outside the United States, the company launched three new dialysis centers and acquired seven dialysis centers.

Which Way Are Estimates Headed?

For 2020, the Zacks Consensus Estimate for revenues is pegged at $11.61 billion, indicating an improvement of 1.9% from the prior-year period. The same for earnings stands at $6.06per share, suggesting growth of 12.2% from the year-ago reported figure.

Other Stocks to Consider

Some other top-ranked stocks from the broader medical space include Accuray Incorporated (NASDAQ:ARAY) , West Pharmaceutical Services, Inc. (NYSE:WST) and The Cooper Companies, Inc. (NYSE:COO) , each currently carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Accuray has an expected earnings growth rate of 200% for third-quarter fiscal 2020.

West Pharmaceutical has an estimated earnings growth rate of 3.4% for first-quarter 2020.

Cooper Companies has a projected long-term earnings growth rate of 10.8%.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Accuray Incorporated (ARAY): Free Stock Analysis Report

DaVita Inc. (DVA): Free Stock Analysis Report

The Cooper Companies, Inc. (COO): Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report

Original post

Here's Why You Should Invest In DaVita (DVA) Stock Right Now
 

Related Articles

Here's Why You Should Invest In DaVita (DVA) Stock Right Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email